Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting

Ener Cagri Dinleyici a,*, Nazan Dalgic b, Sirin Guven c, Ozge Metin d, Olcay Yasa e, Zafer Kurugol f, Ozden Turel g, Gonul Tanir d, Ahmet Sami Yazar c, Vefik Arica h, Mesut Sancar i, Adem Karbuz h, Makbule Eren j, Metehan Ozen h, Ates Kara i, Yvan Vandenplas k

**Faculty of Medicine, Department of Pediatrics, Pediatric Intensive Care and Infectious Disease Unit, Eskisehir Osmangazi University, Eskisehir, Turkey**
**Division of Pediatric Infectious Diseases, Sisli Etfal Training and Research Hospital, Istanbul, Turkey**
**Department of Pediatrics, Umraniye Education & Research Hospital, Istanbul, Turkey**
**Pediatric Infectious Disease Unit, Dr. Sami Ulus Research and Training Hospital of Women’s and Children’s Health and Diseases, Ankara, Turkey**
**Department of Pediatrics, Goztepe Training and Research Hospital, SB Istanbul Medeniyet University, Istanbul, Turkey**
**Department of Pediatrics, Faculty of Medicine, Ege University, Izmir, Turkey**
**Department of Pediatric Infectious Disease Unit, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey**
**Department of Pediatrics, Okmeydani Education and Research Hospital, Istanbul, Turkey**
**Faculty of Pharmacy, Clinical Pharmacy Department, Marmara University, Istanbul, Turkey**
**Faculty of Medicine, Pediatric Infectious Disease Unit, Hacettepe University, Ankara, Turkey**
**Department of Pediatrics, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium**

Received 1 August 2014; accepted 23 October 2014
Available online 16 May 2015

**KEYWORDS**
Lactobacillus reuteri DSM 17938; Diarrhea; Children; Probiotic; Ambulatory care

**Abstract**

**Objective:** Two randomized controlled clinical trials have shown that Lactobacillus (L) reuteri DSM 17938 reduces the duration of diarrhea in children hospitalized due to acute infectious diarrhea. This was the first trial evaluating the efficacy of L. reuteri DSM 17938 in outpatient children with acute infectious diarrhea.

**Methods:** This was a multicenter, randomized, single-blinded, case control clinical trial in children with acute watery diarrhea. A total of 64 children who presented at outpatient clinics were enrolled. The probiotic group received $1 \times 10^8$ CFU L. reuteri DSM 17938 for five days in addition to oral rehydration solution (ORS) and the second group was treated with ORS only.


* Corresponding author.
E-mail: timboothtr@yahoo.com (E.C. Dinleyici).

http://dx.doi.org/10.1016/j.jped.2014.10.009
0021-7557/© 2015 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved.
Introduction

Diarrhea remains an important cause of morbidity and mortality in children worldwide.\(^1\) The European Society of Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) and the European Society of Paediatric Infectious Diseases (ESPID) together published evidence-based guidelines on the management of acute gastroenteritis, and confirmed that rehydration is the key treatment. The guidelines also stated that selected probiotics may reduce the duration and intensity of symptoms and can be used as an adjuvant to oral rehydration solution (ORS).\(^2\) Current evidence also indicates that probiotic effects are strain-specific.\(^3\) Various strains of *Lactobacillus reuteri* species have been studied in acute diarrhea and have been found to be beneficial. *L. reuteri* DSM 17938 is a new probiotic strain with removed transferable resistance traits for tetracycline and lincomycin from the original *L. reuteri* ATCC 55730 strain.\(^4\) It has been previously reported that *L. reuteri* DSM 17938 reduces the duration of diarrhea and the length of hospital stay in children requiring hospitalization due to acute infectious diarrhea.\(^5\) A recent meta-analysis of *L. reuteri* DSM 17938 in children with acute infectious diarrhea showed reduced duration of diarrhea and concluded that outpatient data and country-specific cost-effectiveness analyses are needed.\(^6\) This study is the first report of the effects of *L. reuteri* DSM 17938 on acute infectious diarrhea in an outpatient pediatric setting.
Patient and methods

This was a multicenter, randomized, single-blinded, case control clinical trial in children of both genders, aged between 3 and 60 months, with acute infectious diarrhea (defined as the passage of three or more loose or watery stools per day) lasting 12–72 h before presentation at the outpatient clinic. The main investigator (ECD) did not enroll children and was blinded to the treatment of the patients. Approval for the study was granted by the Local Ethics Committee and an informed consent was obtained from the parents of the children. This study was registered at www.clinicaltrials.gov (NCT01927094).

Children who presented at the outpatient clinic with acute infectious diarrhea, and who were followed up with ambulatory care were enrolled in the study. Exclusion criteria were need for hospitalization, use of antibiotics or probiotics for one month prior to a new episode of diarrhea, severe malnutrition, or severe chronic underlying disease, including immunocompromising conditions.

All children were randomly assigned to the probiotic or control group using a computer-generated randomization list. Block randomization was applied with a computer-generated random number list by the main investigator (ECD), who did not enroll any patients. The first group received the five drops containing $1 \times 10^8$ CFU L. reuteri DSM 17938 (BioGaia®, Stockholm, Sweden) for five days, in addition to ORS. The second group received ORS only (control group). The probiotics preparations were provided by the distribution company (Eczacibasi) in Turkey. Hypo-osmolar ORS (glucose 20 g; sodium 60 mmol/L; potassium 20 mmol/L; bicarbonate 30 mmol/L) was used. The primary endpoint was the duration of diarrhea (in hours). The secondary endpoint was the number of children with diarrhea at each day of the five days of the intervention. Adverse events were also recorded. The duration of diarrhea was defined as the time in hours from admission until cessation of diarrhea, which in turn was defined as the first normal stool according to the Bristol score (a score of <5 was considered as normalization of the stools).

The sample size needed was calculated based on the mean duration of diarrhea and standard deviation (SD) from previous similar studies. With the assumption of mean difference on duration of diarrhea of one day (24 h) between the treatment and control group, the authors calculated that a sample of 64 children would be required for the study to have 80% power with a significance level $= 0.05$ and sigma = 2 (two tailed test). Statistical analysis was performed using SPSS software, version 16.0 (SPSS Inc., IL, USA). Variables were tested for normal distribution and compared using the Mann–Whitney U-test and t-test (for mean difference) and $\chi^2$ or Fisher’s exact tests, as appropriate. MedCalc® program (Microsoft Partner Network, USA) was performed to calculate relative risk (RR). Statistical significance was set at $p < 0.05$.

Results

The study included 64 children. After exclusion of three children from the L. reuteri group and one child from the control group due to antibiotic prescription post-randomization (Fig. 1), a total of 60 remained for evaluation; 29 (20 male, 9 female) in the L. reuteri group and 31 (22 male, nine female) in the control group. The demographic findings, mean duration of diarrhea before intervention and mean number of stools at 24 h prior to inclusion are summarized in Table 1.

The mean duration of diarrhea was significantly reduced in the L. reuteri group when compared to the control group (approximately 15 h; $60.4 \pm 24.5$ h [95% CI: 51.0–69.7 h] vs. $74.3 \pm 15.3$ h [95% CI: 68.7–79.9 h]; $p < 0.05$; Table 2).
**Table 1** Demographic and clinical findings of the study groups.

<table>
<thead>
<tr>
<th></th>
<th>Lactobacillus reuteri DSM 17938 (n = 29)</th>
<th>Control group (n = 31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (months)</td>
<td>27.9 ± 18.2</td>
<td>22.6 ± 14.4</td>
</tr>
<tr>
<td>Gender</td>
<td>20 boys, 9 girls</td>
<td>22 boys, 9 girls</td>
</tr>
<tr>
<td>Mean number of stools</td>
<td>7.13 ± 3.8</td>
<td>6.1 ± 0.9</td>
</tr>
<tr>
<td>during the 24h prior</td>
<td></td>
<td></td>
</tr>
<tr>
<td>to inclusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean duration of diarrhea before intervention (hours)</td>
<td>18.1 ± 6.5</td>
<td>20.1 ± 8.7</td>
</tr>
</tbody>
</table>

Values expressed as mean ± SD.

**Table 2** Duration of diarrhea in study groups.

<table>
<thead>
<tr>
<th></th>
<th>Lactobacillus reuteri DSM 17938 (n = 29)</th>
<th>Control group (n = 31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of diarrhea</td>
<td>60.4 ± 24.5^a</td>
<td>74.3 ± 15.3</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SD (95% CI). ^a p = 0.01; L. reuteri vs. control group.

At the 48th hour of the study, 45% of the children receiving L. reuteri DSM 17938 had watery diarrhea, while this was still the case in 87% of the children in the control group (13/29; 44.8% vs. 27/31; 87%; RR: 0.51; 95% CI: 0.34–0.79; p < 0.01). From the 72nd hour of the intervention, the percentage of children without diarrhea was similar between the groups (Table 3). No adverse effects related to L. reuteri DSM 17938 were observed.

**Discussion**

The results of the present study showed that ORS in combination with five days of L. reuteri DSM 17938 reduced the duration of acute infectious diarrhea to approximately 15 h in children aged between 3 and 60 months. The effect was mainly observed after 48 h of intervention, when 55% of the children in the intervention group were diarrhea-free, while this was the case in only 13% in the control group. In a previous study, performed by the same study team and with the same design, except for the fact that the study was applied to hospitalized children, 127 children aged 3–60 months were enrolled. In hospitalized children, the administration of L. reuteri DSM 17938 reduced the duration of diarrhea significantly to approximately 33 h. The effect (percentage of children without diarrhea) of L. reuteri DSM 17938 started to be observed after 24 h of intervention and was greatest after 48 and 72 h. It was observed also that the mean length of hospital stay was shortened by more than 24 h in the L. reuteri DSM 17938 group. Francavilla et al. performed a randomized double-blinded, placebo-controlled clinical trial on 74 children aged 6–36 months with acute diarrhea, randomized to receive L. reuteri DSM 17938 or placebo for seven days, in three hospitals in Southern Italy. Compared with the placebo group, the L. reuteri DSM 17938 group presented a significant reduction in the duration of diarrhea, in the risk of watery diarrhea on day 2 and day 3, and in the risk of relapse of diarrhea, although no reduction of the duration of hospitalization was observed. Szajewska et al. pooled the data from these two RCTs of hospitalized children, confirming that L. reuteri DSM 17938 significantly reduced the duration of diarrhea to approximately 32 h and increased the chance of cure on day 3. Two independent studies, one in Indonesia and one in Mexico, demonstrated that the prophylactic use of L. reuteri DSM 17938 reduces the frequency and duration of diarrheal episodes, although their clinical relevance can be questioned. L. reuteri DSM 17938 was well tolerated, and no associated adverse events have been reported in any trial.

The current study had some limitations, as it was not a double-blinded, placebo-controlled clinical trial. To access stool consistency, the Bristol Stool Form Scale was used, which has a limited validation for the youngest children, although it offers a more objective form of assessing stool consistency rather than just relying on the perceptions of caregivers. The duration of diarrhea was used as the primary endpoint, which is not considered optimal. However, there is a major reluctance of caregivers and healthcare providers to conduct the cumbersome stool collection. The question of generalization of findings in clinical trials, specifically on infectious gastroenteritis and probiotics, is challenging. However, these findings can be considered as generalized, since worldwide viral gastroenteritis is the most common cause. Moreover, as a multi-center study, the participants came from urban and rural regions, including economically developed and poor areas. Therefore, these findings are likely to allow for generalization.

The Working Group on Probiotics of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition

**Table 3** Percentage of children with diarrhea in study groups.

<table>
<thead>
<tr>
<th></th>
<th>Lactobacillus reuteri DSM 17938 (n = 29)</th>
<th>Control group (n = 31)</th>
<th>Relative risk (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>24th hour</td>
<td>25/29 (86.2%)</td>
<td>31/31 (100%)</td>
<td>0.86 (0.74–1.01)</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>48th hour</td>
<td>13/29 (44.8%)</td>
<td>27/31 (87.0%)</td>
<td>0.51 (0.34–0.79)</td>
<td>p &lt; 0.01</td>
</tr>
<tr>
<td>72nd hour</td>
<td>5/29 (17.2%)</td>
<td>4/31 (12.9%)</td>
<td>1.34 (0.4–4.5)</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>96th hour</td>
<td>1/29 (3.4%)</td>
<td>1/31 (3.2%)</td>
<td>1.07 (0.07–16.3)</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>120th hour</td>
<td>0/29 (0%)</td>
<td>0/31 (0%)</td>
<td>NA</td>
<td>p &gt; 0.05</td>
</tr>
</tbody>
</table>
(ESPGHAN) concluded that the use of *L. reuteri* DSM 17938 should be considered in the management of acute gastroenteritis as an adjunct intervention to ORS. Probiotics may be of help for the management of acute diarrhea. However, the effect is strain-specific, and efficacy needs to be proven in different settings, such as hospital or outpatients settings. The results of the present study have shown that *L. reuteri* DSM 17938 as an adjunct to ORS therapy is efficacious in the treatment of acute diarrhea, reducing the duration of the disease in an outpatient setting.

**Conflicts of interest**

E.C. Dinleyici is speaker bureau and advisory board member of Biocodex. M. Ozen is speaker bureau of Pfizer Consumer Health. Y. Vandenplas is a consultant for Biocodex, United Pharmaceuticals. Other authors declare no conflicts of interest.

**References**

10. Vandenplas Y. *Lactobacillus reuteri* is an effective option for the prevention of diarrhoea in preschool children but may not be cost-effective in all settings. Evid Based Med. 2014;19:212.